2001
DOI: 10.1016/s0378-4347(00)00442-4
|View full text |Cite
|
Sign up to set email alerts
|

Distribution of the hallucinogens N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine in rat brain following intraperitoneal injection: application of a new solid-phase extraction LC–APcI–MS–MS–isotope dilution method

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
12
0
2

Year Published

2001
2001
2011
2011

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 20 publications
(16 citation statements)
references
References 53 publications
2
12
0
2
Order By: Relevance
“…Therefore, this study focuses on measurement of 5-MeO-DMT concentrations in the whole brain after intraperitoneal administration. Consistent with previous findings (Barker et al, 2001), 5-MeO-DMT is capable of penetrating the blood-brain barrier and accumulating within animal brains. The most significant finding is the greater than proportional increase of brain 5-MeO-DMT concentration with the increase in dose (Fig.…”
Section: Discussionsupporting
confidence: 92%
See 1 more Smart Citation
“…Therefore, this study focuses on measurement of 5-MeO-DMT concentrations in the whole brain after intraperitoneal administration. Consistent with previous findings (Barker et al, 2001), 5-MeO-DMT is capable of penetrating the blood-brain barrier and accumulating within animal brains. The most significant finding is the greater than proportional increase of brain 5-MeO-DMT concentration with the increase in dose (Fig.…”
Section: Discussionsupporting
confidence: 92%
“…The O-demethylation mediated by CYP2D6 produces an active metabolite, bufotenine (Yu et al, 2003a). In addition, each study on the metabolism and disposition of 5-MeO-DMT was limited to a single dose (Agurell et al, 1969;Sitaram et al, 1987a,b;Barker et al, 2001;Shen et al, 2009Shen et al, , 2010b. Therefore, in this study we investigated 5-MeO-DMT pharmacokinetics in mice at multiple dose levels and through different routes of administration, which cover the range from nontoxic to toxic dose levels, aiming to define the pharmacokinetic properties of 5-MeO-DMT, delineate the impact of CYP2D6 on systemic clearance of 5-MeO-DMT, and develop a pharmacokinetic model to quantitatively characterize serum concentration-time profiles of 5-MeO-DMT.…”
mentioning
confidence: 99%
“…[3][4][5][6] Notably, DMT occurs naturally in the mammalian brain as a neurotransmitter. [7][8][9][10][11][12] Diethyl-tryptamine (DET) is an orally active hallucinogenic drug and psychedelic compound with effects that last for a moderate duration. The DET is a substituted for diethyl groups and structurally similar to DMT and dipropyltryptamine (DPT).…”
Section: Introductionmentioning
confidence: 99%
“…These included a 24 h reflux with deuterated acids. 17,19,35 Two examples have recently been reported for the synthesis of N,N-d 10 -DET and N,N-d 6 -DPT via tryptamine alkylation with d 5 -iodoethane and 1,1,1-d 3 -3-bromopropane, respectively. In both cases the reaction mixture was stirred for 5 days.…”
Section: Resultsmentioning
confidence: 99%
“…1,3,[16][17][18] Rat brain levels of DMT and 5-MeO-DMT have been determined successfully following intraperitoneal (IP) injection and an isotope dilution method was successfully employed using deuterated DMT and 5-MeO-DMT as internal standards. 19 The use of a,a,b,b-d 4 derivatives provided indications for a differential pharmacological response when compared with nondeuterated tryptamines which merits further investigations. This has been attributed to the in vivo kinetic isotope effect where, for example, d 4 -DMT was observed to exhibit prolonged behavioural effects in rats.…”
Section: Introductionmentioning
confidence: 99%